Complete inhibition of in vivo glioma growth by oncostatin M.
We describe here the oncostatin M (OSM)-dependent inhibition of in vivo tumour formation after intracerebral inoculation of glioblastoma cells in mice. We generated human glioblastoma cells transfected with the OSM gene under the control of a tetracycline-response promoter. Upon removal of tetracycline from the medium, cells exhibited a differentiated cell morphology, while proliferation was significantly inhibited. After implantation of these cells into nude mice brains, large tumours developed in animals lacking OSM expression, whereas no tumour formation was observed in mice with induced OSM expression. Our results suggest that OSM exerts pronounced antitumorigenic effects on glioblastoma cells in vivo and provide arguments for a therapeutic application of OSM in humans.
Friedrich
M
M
Department of Neurology, University of Münster, Münster, Germany.
Höss
N
N
Stögbauer
F
F
Senner
V
V
Paulus
W
W
Ringelstein
E B
EB
Halfter
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D005910:Glioma / Q000473:pathology*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D053683:Oncostatin M; D010455:Peptides / Q000235:genetics / Q000502:physiology*; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins / Q000378:metabolism; D013752:Tetracycline / Q000494:pharmacology; D014162:Transfection; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C508351:OSM protein, human; C508352:Osm protein, mouse; D010455:Peptides; D011994:Recombinant Proteins; D053683:Oncostatin M; D013752:Tetracycline